Strattera Labeling Adds Bolded Warning For Severe Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly revises labeling following two cases of severe liver injury attributed to the attention deficit/hyperactivity disorder treatment. The company plans to issue a "Dear Health Care Professional" letter Jan. 3.
You may also be interested in...
FDA Issues Strattera Public Health Advisory On Suicidal Thinking
Advisory alerts physicians to the risk of suicidal thinking in children and adolescents related to use of Eli Lilly's ADHD therapy atomoxetine.
FDA Issues Strattera Public Health Advisory On Suicidal Thinking
Advisory alerts physicians to the risk of suicidal thinking in children and adolescents related to use of Eli Lilly's ADHD therapy atomoxetine.
ADHD Market Hurt By Safety Concerns, Lilly Says
Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.